14-3-3η Protein, Disease Activity and Bone Mineral Density, in Female Patients With Rheumatoid Arthritis
- Conditions
- OsteoporosisRheumatoid Arthritis
- Interventions
- Diagnostic Test: 14-3-3η Protein assay
- Registration Number
- NCT03999528
- Lead Sponsor
- Al-Azhar University
- Brief Summary
Is to investigate the relation between 14-3-3η protein, disease activity, and bone mineral density in female patients with rheumatoid arthritis.
- Detailed Description
Methods: all patients in the study will subject to:
* Clinical assessment, WT, Height ,BMI, parity, medications,
* DAS 28.
* Serum 14-3-3η protein.
* DEXA scan.
Grouping:
* Group I: RA Patients with low BMD.
* Group II: RA Patients with normal BMD.
* Group III: normal control.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 45
- Rheumatoid arthritis according to ACR 2010 criteria with at least one year duration.
- Premenopausal females.
- On conventional DMARD with maximum 5 mg steroids.
- Biological treatment.
- Previous antiresorptive treatment, or bone anabolics.
- High dose corticosteroid.
- Chronic renal or kidney disease.
- Medications affecting bone metabolism.
- Thyroid or adrenal dysfunction,
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description control group 14-3-3η Protein assay normal control study group 14-3-3η Protein assay RA Patients
- Primary Outcome Measures
Name Time Method 14-3-3η Protein and RA disease activity three months percent of active RA disease and study the correlation between 14-3-3η Protein and RA disease activity
- Secondary Outcome Measures
Name Time Method 14-3-3η Protein and osteoporosis in RA patients three months percent of low BMD and study the correlation between 14-3-3η Protein and osteoporosis in RA patients
Trial Locations
- Locations (1)
Al-Azhar Faculty of medicine, Rheumatology Department
🇪🇬Cairo, Egypt